NAOS Emerging Opportunities Company Limited (ASX: NCC) delivered a robust FY26 with a 2416% surge in after-tax profit and an 18.7% portfolio return, outperforming the benchmark by over 10%. The company raised its fully franked dividend by 5%, signaling confidence amid a challenging market.
- FY26 after-tax profit up 2416% to $7.14 million
- Investment portfolio returned +18.72%, beating benchmark by 10.61%
- Full year dividend increased 5% to 4.20 cents per share, fully franked
- Post-tax net tangible assets per share rose to $0.55
- Convertible note buy-back and dividend reinvestment plan maintained
Profit and Dividend Growth Amid Market Headwinds
NAOS Emerging Opportunities Company Limited (ASX:NCC) reported a striking turnaround for the financial year ended 30 June 2026, with after-tax profit attributable to shareholders soaring 2416% to $7.14 million. This was driven by a 194% jump in revenue to $10.33 million and a stellar investment portfolio return of +18.72%, comfortably outperforming the S&P/ASX Small Ordinaries Accumulation Index by 10.61%.
The company’s Board declared a fully franked final dividend of 2.10 cents per share, matching the interim dividend and bringing the full-year payout to 4.20 cents, a 5% increase on FY25 and the first rise since FY21. This dividend yield stands at an impressive 11.35%, or 15.14% when including franking credits, underscoring NCC’s commitment to delivering sustainable income streams to shareholders.
Portfolio Performance and Key Investments
Despite a challenging macroeconomic backdrop marked by rising interest rates and persistent inflation, NCC’s investment portfolio excelled. Key contributors included Pharmx Technologies Ltd, which secured a strategic alliance with Sigma Healthcare Ltd, and Firmus Grid Ltd, advancing its AI factory projects. The portfolio’s concentrated exposure to emerging Australian and New Zealand companies, with over 90% outside ASX indices, continues to differentiate NCC from its benchmark.
Pharmx’s partnership with Sigma Healthcare is a notable highlight, positioning Pharmx as the preferred electronic data interchange provider for a dominant player in the pharmacy sector. This alliance is expected to fuel revenue growth through marketplace expansion, international scaling, and data monetisation.
Schoolblazer Ltd’s Australian expansion also gained momentum, securing several independent school contracts and progressing group consolidation to unlock operational efficiencies. Meanwhile, Saunders International Ltd and Big River Industries Ltd are positioned to benefit from defence sector contracts and strategic acquisitions, respectively.
Capital Management and Shareholder Alignment
Capital management remained a focus, with NCC executing an on-market buy-back of 1,705 convertible notes at a discount, reducing interest costs and enhancing value for remaining noteholders. The dividend reinvestment plan operated without dilution, with all entitlements satisfied through on-market purchases.
The Board’s alignment with shareholders is evident, holding approximately 6.4% of the company’s shares collectively. Post-year-end, the portfolio returned an additional +8.75% in July 2026, indicating ongoing momentum.
Outlook and Strategic Focus
Looking ahead to FY27, NCC anticipates several catalysts across its portfolio, including further disclosures on Pharmx’s strategic agreement, defence contract wins for Saunders International, and operational milestones for Firmus Grid’s AI factories. The company also plans to diversify its portfolio further, aiming to balance risk and reduce concentration.
NAOS Asset Management, NCC’s Investment Manager, continues to emphasize a disciplined, long-term investment philosophy centered on emerging companies with strong management alignment and structural growth opportunities. The company’s Certified B Corporation status reflects a commitment to positive social and environmental impact alongside financial performance.
While the macroeconomic environment remains uncertain, NCC’s robust FY26 results and strategic positioning suggest a resilient platform for future value creation.
Bottom Line?
NAOS Emerging Opportunities has delivered a standout FY26 performance with strong profit growth and dividend uplift, but sustaining this momentum will hinge on execution across a concentrated portfolio facing evolving macro and sector dynamics.
Questions in the middle?
- How will Pharmx Technologies capitalise on its strategic alliance with Sigma Healthcare to drive long-term revenue growth?
- Can NCC balance its portfolio concentration with diversification to mitigate sector-specific risks in FY27?
- What impact will rising interest rates and geopolitical tensions have on NCC’s emerging companies exposure?